Ablynx company information, Employees & Contact Information

Sanofi to Buy Ablynx for nearly €4 billion CHEManager

Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B Labiotech.eu

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells PNAS

Ablynx and Novo Nordisk in Nanobody drug discovery collaboration Drug Target Review

Sanofi snaps up Ablynx after underwhelming Novo bid BioPharma Dive

Sanofi: ‘Ablynx Nanobody Tech Will Fuel Innovation’ BioProcess International

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen News-Medical

Sanofi’s first product from the Ablynx deal scores CHMP backing as it looks for $500M in peak sales Fierce Pharma

Sanofi cuts programs tied to multibillion-dollar deals from pipeline Fierce Biotech

France's Sanofi buys Ablynx for $4.8 billion in biotech mergers and acquisitions boom CNBC

Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook Frontiers

LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company SynBioBeta

Novo Nordisk puts $3B on the table for Ablynx BioPharma Dive

Edwin Moses on how Ablynx has made it to the top of European biotech Labiotech.eu

Sanofi inks €3.9B Ablynx buyout to pip Novo in M&A fight Fierce Biotech

Ablynx’s anti-inflammation drug fails in lupus BioPharma Dive

Ablynx’s caplacizumab hits primary endpoint in phase 3 Fierce Biotech

Merck Outsources the Development of its Nanobody for Psoriasis Labiotech.eu

Ablynx prepares path for lead drug after positive late-stage results BioPharma Dive

The EMA Approves the First Nanobody from Ablynx Labiotech.eu

Optimizing expression of Nanobody® molecules in Pichia pastoris through co-expression of auxiliary proteins under methanol and methanol-free conditions Microbial Cell Factories

Sanofi to Acquire Ablynx for $4.8B Genetic Engineering and Biotechnology News

Sanofi offers Ablynx billions of biobucks for nanobody partnership Fierce Biotech

Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds Fierce Biotech

Novo makes €2.6B Ablynx buyout bid public after being rebuffed Fierce Biotech

Hard-hit Novo Nordisk still has M&A 'on the radar' post-Ablynx setback, CEO says Fierce Pharma

No Deal for Novo as Sanofi Swoops in With $4.85B Win for Ablynx BioSpace

LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company Business Wire

Sanofi’s first Ablynx drug, rare blood disorder treatment Cablivi, clears final EU hurdle Fierce Pharma

Sanofi to acquire Ablynx for €3.9 Billion Science|Business

Ablynx files rare blood disorder drug, raising prospect of first commercial product next year Fierce Biotech

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters

Full article: Engineered CH2 domains (nanoantibodies) Taylor & Francis Online

Large Diversity of Functional Nanobodies from a Camelid Immune Library Revealed by an Alternative Analysis of Next-Generation Sequencing Data Frontiers

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura The New England Journal of Medicine

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex Frontiers

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid Reuters

AbbVie Opts Against Licensing Ablynx’s Vobarilizumab Genetic Engineering and Biotechnology News

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura The New England Journal of Medicine

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions Frontiers

Ablynx’ vobarilizumab fails in lupus trial PharmaTimes

Ablynx takes Phase III hurdle in acquired TTP European Biotechnology Magazine

Sanofi gets EU OK for Ablynx flagship drug Cablivi PMLiVE

Born from frozen camel blood, Ablynx is $4.8 billion prize The Napa Valley Register

Ablynx Earns $3M from Pfizer as Second Anti-TNF-Alpha Nanobody Enters Clinic Genetic Engineering and Biotechnology News

Ablynx: Chief of business European Biotechnology Magazine

Ablynx appoints Markus Ewert as chief business officer PMLiVE

A Look at Ablynx and Sanofi’s Existing Partnership Market Realist